The FDA on December 4, 2024, granted accelerated approval to BIZENGRI® for adults with the following:
Advanced, unresectable, or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring a Neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy, or
Advanced, unresectable, or metastatic Pancreatic adenocarcinoma harboring a NRG1 gene fusion with disease progression on or after prior systemic therapy.
BIZENGRI® is a product of Merus N.V.
